原发中枢神经系统淋巴瘤预后因素研究进展  

Research progress on prognostic factors of primary central nervous system lymphoma

作　　者：王烁婷 高洁 沈千青 贾永前[1] WANG Shuoting;GAO Jie;SHEN Qianqing;JIA Yongqian(Department of Hematology,West China Hospital of Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院血液科,四川成都610041

出　　处：《中国输血杂志》2021年第4期428-431,共4页Chinese Journal of Blood Transfusion

摘　　要：原发性中枢神经系统淋巴瘤(PCNSL)是1种罕见且特殊的非霍奇金淋巴瘤。基于大剂量甲氨蝶呤(high-dose methotrexate, HD-MTX)的诱导化疗被认为是初诊PCNSL的标准治疗方法,但PCNSL因其高侵袭性和高复发率,预后往往不佳。诊断时对PCNSL进行危险分层及预后评估在临床治疗中尤为重要。目前国际上大多使用MSKCC(The Memorial Sloan-Kettering Cancer Center)、国际结外淋巴瘤研究小组(The International Extranodal Lymphoma Study Group, IELSG)、诺丁汉/巴塞罗那3种评分模型来对PCNSL进行危险分层及预后评估,但随着对PCNSL的免疫组织学、分子遗传学等深入认识,可供评价预后的潜在因素不断涌现。Primary central nervous system lymphoma(PCNSL) is a rare and special kind of non-Hodgkin lymphoma. Chemotherapy based on high-dose methotrexate(HD-MTX) is considered a standard therapy for newly diagnosed PCNSL, but the prognosis of PCNSL is poor due to its high invasiveness and recurrence rate. Risk stratification and prognosis assessment of PCNSL in diagnosis is particularly important in clinical treatment. At present, MSKCC(the Memorial Sloan Kettering Cancer Center), the International Extranodal Lymphoma Study Group(IELSG) and Nottingham/Barcelona scoring models are mostly used to classify the risk and evaluate the prognosis of PCNSL. With the further understanding of immunohistochemistry and molecular genetics of PCNSL, potential prognostic factors continue to emerge.

关 键 词：原发中枢神经系统淋巴瘤 预后因素 微小RNA 循环肿瘤DNA 

分 类 号：R457.1[医药卫生—治疗学] R739.4[医药卫生—临床医学]